Retina Institute Japan and Dainippon Sumitomo Pharma Co., Ltd. Form a Capital Alliance Towards the Development of Nobel Prize Winning iPS Cell Technology
3/29/2013 9:07:02 AM
TOKYO--(BUSINESS WIRE)--Retina Institute Japan K.K. (RIJ) (Headquarters: Fukuoka, Japan; President: Hardy T S Kagimoto, MD) and Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announce today that the two companies signed an agreement (Agreement) that DSP invests into RIJ to discuss alliance to put iPS cell technology to practical use. Under the Agreement, DSP has subscribed for 1.5 billion JPY of third party allocation of shares by RIJ. DSP will exclusively discuss with RIJ to collaborate in and outside Japan to use groundbreaking iPS cell technology to cure Age-related Macular Degeneration.
comments powered by